1. Home
  2. WVE vs SDHC Comparison

WVE vs SDHC Comparison

Compare WVE & SDHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WVE
  • SDHC
  • Stock Information
  • Founded
  • WVE 2012
  • SDHC 2008
  • Country
  • WVE Singapore
  • SDHC United States
  • Employees
  • WVE N/A
  • SDHC N/A
  • Industry
  • WVE Biotechnology: Pharmaceutical Preparations
  • SDHC
  • Sector
  • WVE Health Care
  • SDHC
  • Exchange
  • WVE Nasdaq
  • SDHC Nasdaq
  • Market Cap
  • WVE 939.3M
  • SDHC 976.1M
  • IPO Year
  • WVE 2015
  • SDHC 2024
  • Fundamental
  • Price
  • WVE $6.35
  • SDHC $20.25
  • Analyst Decision
  • WVE Strong Buy
  • SDHC Hold
  • Analyst Count
  • WVE 11
  • SDHC 4
  • Target Price
  • WVE $20.91
  • SDHC $30.25
  • AVG Volume (30 Days)
  • WVE 1.7M
  • SDHC 36.2K
  • Earning Date
  • WVE 05-08-2025
  • SDHC 05-14-2025
  • Dividend Yield
  • WVE N/A
  • SDHC N/A
  • EPS Growth
  • WVE N/A
  • SDHC N/A
  • EPS
  • WVE N/A
  • SDHC 0.24
  • Revenue
  • WVE $104,939,000.00
  • SDHC $1,010,976,000.00
  • Revenue This Year
  • WVE N/A
  • SDHC $6.82
  • Revenue Next Year
  • WVE N/A
  • SDHC $11.61
  • P/E Ratio
  • WVE N/A
  • SDHC $82.77
  • Revenue Growth
  • WVE N/A
  • SDHC 28.67
  • 52 Week Low
  • WVE $4.25
  • SDHC $17.03
  • 52 Week High
  • WVE $16.74
  • SDHC $39.50
  • Technical
  • Relative Strength Index (RSI)
  • WVE 40.37
  • SDHC 55.12
  • Support Level
  • WVE $5.62
  • SDHC $18.56
  • Resistance Level
  • WVE $7.07
  • SDHC $21.08
  • Average True Range (ATR)
  • WVE 0.60
  • SDHC 0.76
  • MACD
  • WVE 0.01
  • SDHC 0.15
  • Stochastic Oscillator
  • WVE 26.35
  • SDHC 67.20

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About SDHC Smith Douglas Homes Corp.

Smith Douglas Homes Corp is a company engaged in the design, construction, and sale of single-family homes in some of the highest growth and desirable markets in the Southeastern United States. It is organized into eight geographical divisions which comprise two reportable segments. Its Southeast segment consists of Atlanta, Central Georgia, Charlotte, Greenville, and Raleigh divisions. Its Central segment consists of Alabama, Houston, and Nashville divisions.

Share on Social Networks: